Read our inaugural articles and submit your next manuscript

Juan Carlos Ivancevich Tuesday, 21 July 2015 12:36




Editor-in-Chief: Juan Celedón (USA) and Giovanni Passalacqua (Italy)

Submit a manuscript

Editorial Board

Author Instructions

Article Alerts

Dear Colleague,

We are pleased to announce that Asthma Research and Practice has published its first articles with BioMed Central. We hope that you find some of the inaugural articles below of interest.

Inaugural Articles



Asthma research and practice: a new journey begins

Juan Celedon, Giovanni Passalacqua, Giorgio Canonica

Full Text | PDF



Asthma and obesity: mechanisms and clinical implications

Cynthia Baffi, Daniel Winnica, Fernando Holguin

Abstract | Full Text | PDF



The patient with rhinitis in the pharmacy. A cross-sectional study in real life

Carlo Lombardi, Eleonora Musicco, Francesco Rastrelli, Germano Bettoncelli, Giovanni Passalacqua, Giorgio Canonica

Abstract | Full Text | PDF



Vitamin D supplementation decreases Aspergillus fumigatus specific Th2 responses in CF patients with aspergillus sensitization: a phase one open-label study

Nikki Nguyen, Joseph Pilewski, Juan Celedón, Sivanarayana Mandalapu, Megan Blanchard, Adrienne DeRicco, Elizabeth Hartigan, John Alcorn, Jay Kolls

Abstract | Full Text | PDF


About the journal

Asthma Research and Practice will publish articles related to basic asthma research, clinical practice as well as translational research. The journal aims to publish the most recent and relevant information on asthma and related disorders (such as rhinitis, COPD overlapping syndrome, sinusitis).

Reasons to publish in Asthma Research and Practice


High quality peer review service


Expert international Editorial Board


Rapid publication upon acceptance


Widest possible global dissemination of your research


Keep up to date

Sign up for article alerts to keep up to date with essential research from Asthma Research and Practice.

Sincerely yours,

Juan Celedón and Giovanni Passalacqua

Editors-in-Chief, Asthma Research and Practice

 Follow BioMed Central:      

How to ensure BioMed Central's emails reach your inbox.

You have received this message because you have asked for updates from Asthma Research and Practice.

To change your email preferences please login to:

To unsubscribe as a registrant please visit our journal unsubscribe page.

For further information or enquiries please contact Customer Services at: This email address is being protected from spambots. You need JavaScript enabled to view it. .

BioMed Central Ltd, 236 Gray's Inn Road, London, WC1X 8HB, United Kingdom.

Part of Springer Science+Business Media. Privacy Policy.







Allergen immunotherapy in asthma; what is new?

Juan Carlos Ivancevich Thursday, 16 July 2015 12:16

Open Access


Giovanni Passalacqua*Anthi RogkakouMarcello Mincarini and Giorgio Walter Canonica

  • *Corresponding author: Giovanni Passalacqua This email address is being protected from spambots. You need JavaScript enabled to view it.

Author Affiliations

For all author emails, please log on.


The use and role of allergen immunotherapy (AIT) in asthma is still a matter of debate, and no definite recommendation about this is made in guidelines, both for the subcutaneous and sublingual routes. This is essentially due to the fact that most controlled randomised trials were not specifically designed for asthma, and that objective measures of pulmonary function were only occasionally considered. Nonetheless, in many trials, favourable results in asthma (symptoms, medication usage, bronchial reactivity) were consistently reported. There are also several meta analyses in favour of AIT, although their validity is limited by a relevant methodological heterogeneity. In addition to the crude clinical effect, a disease modifying action of AIT (prevention of asthma onset and long-lasting effects) have been reported. The safety is an important aspect to consider in asthma. Fatalities were rare: in Europe no fatality was reported in the last three decades, as in the United States in the last 4 years. Based on previous surveys, and common sense, uncontrolled asthma is still recognized as the most important risk factor for severe adverse events. On the contrary, there is no evidence that AIT can worsen or induce asthma. According to the available evidence, AIT can be safely used as add-on treatment when asthma is associated with rhinitis (a frequent condition), provided that asthma is adequately controlled by pharmacotherapy. AIT cannot be recommended or suggested as single therapy. When asthma is the unique manifestation of respiratory allergy, its use should be evaluated case by case.


Allergen immunotherapy; Sublingual immunotherapy; Subcutaneous immunotherapy; Efficacy; Safety; Allergic asthma; Allergic rhinitis; Adverse events 

Viewing options


The following new article has just been published in Asthma Research and Practice

Juan Carlos Ivancevich Friday, 03 July 2015 12:28


Article alert


Exercise-induced bronchoconstriction: new evidence in pathogenesis, diagnosis and treatment

Bonini M, Palange P

Asthma Research and Practice 2015, 1 :2 (2 July 2015)

Abstract | Full Text | PDF

Asthma Research and Practice: the official journal of Interasma

Juan Carlos Ivancevich Tuesday, 23 June 2015 11:26

Dear Society member,
We are very pleased to inform you that
Asthma Research and Practice (ARP) has now officially launched and published its first articles. ARP is the official journal of Interasma – the Global Asthma Association and is led by joint Editors-in-Chief, Juan Celedón (USA) and Giovanni Passalaqua (Italy). The Open Access, peer-reviewed journal aims to spread international awareness and knowledge about the growing burden of asthma by publishing basic, clinical and translational research concerning asthma and related disorders.
ARP aims to serve as an international platform for the dissemination of research of interest to pulmonologists, allergologists, primary care physicians and family doctors, ENTs and other health care providers interested in asthma, its mechanisms and comorbidities.
You can read all of the publications, including the launch Editorial, on the journal website: The journal will be published continuously online-only and so
we encourage you to sign up to receive free email alerts to keep up to date with all of the latest research. You can do this by registeringhere.    
As an Interasma society member, please do help us spread the word about the journal by encouraging colleagues to submit their manuscripts and by submitting high quality work yourself. Don’t forget we have also have a range of materials available to help you support us in letting people know about the journal, for example if you are attending any meetings relevant to the journal’s scope.
Thank you for your support so far, we look forward to working with you to build the success of Asthma Research and Practice!
With best wishes,
Juan Celedón, jointEditor-in-Chief
Giovanni Passalacqua, jointEditor-in-Chief
Holly Young
Journal Development Editor

236 Gray's Inn Road
London, WC1X 8HB
United Kingdom

T: +44 (0)20 3192 2153
This email address is being protected from spambots. You need JavaScript enabled to view it.

The patient with rhinitis in the pharmacy. A cross-sectional study in real life

Juan Carlos Ivancevich Sunday, 14 June 2015 02:01
Open Access

Carlo Lombardi1Eleonora Musicco1Francesco Rastrelli2Germano Bettoncelli3Giovanni Passalacqua4* and Giorgio Walter Canonica4

  • *Corresponding author: Giovanni Passalacqua This email address is being protected from spambots. You need JavaScript enabled to view it.

Author Affiliations

For all author emails, please log on.



In the practical management of allergic rhinitis (AR), pharmacists are usually the first-line contact, also because some medications are available as over the counter. Therefore, pharmacists may represent an important resource, in mediating the interaction between patients and physicians. We evaluated the clinical/demographic characteristics of patients with respiratory allergies who consulted their pharmacists as first-line contact. A patient-oriented questionnaire was developed by a scientific committee including pharmacists, GPs, allergists, pulmonologists and ENT specialists.


The questionnaire consisted of items covering the general aspects of AR. Allergic Rhinitis and its Impact on Asthma guidelines were assumed as reference for diagnosis and therapy. The questionnaire was distributed to pharmacies, and pharmacists were asked to deliver the questionnaire to all patients referring for nasal symptoms.


30 pharmacies were involved during the pollen season 2011, and 410 patients (55 % male) participated. The most frequent complaints were 20 rhinitis (49 %) and conjunctivitis (29 %), followed by lower respiratory symptoms (cough and/or dyspnea). Isolated conjunctival symptoms were present in only 22 % of patients. Among patients with lower respiratory symptoms, cough was the most frequent, variously associated with upper respiratory symptoms or overt dyspnea. Dyspnea alone was present in 16 % of patients. 39 % of patients had no physician-based diagnosis. Oral antihistamines were the most used self-medication, followed by intranasal decongestants. 30 % of respondents had used alternative medicines.


According to these data, AR is still considered a trivial disease, frequently self-managed, with over the counter medications, not in line with guidelines. A physician-based diagnosis is present in about 60 % of patients.


Respiratory allergy; Allergic rhinitis; Allergic asthma; Pharmacist 

Asthma and obesity: mechanisms and clinical implications

Juan Carlos Ivancevich Friday, 12 June 2015 14:23
Open Access

Cynthia Wilson BaffiDaniel Efrain Winnica and Fernando Holguin


Obesity is the most common asthma co-morbidity; it has been associated with increased risk for asthma exacerbations, worse respiratory symptoms and poor control. The exact mechanisms remain elusive and are probably multifactorial, stemming from mechanical alterations of the airways and lung parenchyma, to systemic and airway inflammatory and metabolic dysregulation that adversely influences lung function and or response to therapy. However, the fact that not every obese asthmatic is equally affected by weight gain highlights the many challenges and complexities in understanding this association. The factors that determine susceptibility may not depend on being obese alone, but rather the interactions with other phenotypical characteristics, such as age of asthma onset, gender and race to name a few. Inability to account for asthma phenotypes that are differentially affected by increasing body mass index (BMI) may contribute to the lack of consistent results across studies. This review will provide a succinct summary of obesity-related mechanisms and the clinical impact on asthma including highlights on recent progress.

Keywords: Obesity; Asthma; Obese asthma phenotype 

Asthma research and practice: a new journey begins

Juan Carlos Ivancevich Wednesday, 10 June 2015 15:47

Juan C. Celedon1*Giovanni Passalacqua2 and Giorgio Walter Canonica2

  • *Corresponding author: Juan C Celedon This email address is being protected from spambots. You need JavaScript enabled to view it.

Author Affiliations

1Division of Pediatric Pulmonary Medicine, Allergy and Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania

2Allergy and Respiratory Diseases, Department of Internal Medicine, IRCCS San Martino Hospital-IST-University of Genoa, Genova, Italy

For all author emails, please log on.

Asthma Research and Practice 2015, 1:5  doi:10.1186/s40733-015-0005-3

The electronic version of this article is the complete one and can be found online at:Missingcontent/1/1/5

© 2015 Celedon et al.; licensee BioMed Central. 


As co-Editors in Chief (and Professor Canonica as President of Interasma), it is our pleasure to welcome our colleagues to this first issue of the journal Asthma Research and Practice (ARP[1]. This will be an open-access online journal, and thus easily accessible to a large audience. The aims and scope of ARP will be to publish original research articles and state of the art reviews focusing on risk factors, diagnosis and management of asthma at all ages. Since asthma is a disease that comprises diverse endotypes and is often accompanied by co-morbidities, we expect and welcome manuscripts on topics such as “obese asthma”, exercise-induced asthma, asthma-COPD overlap syndrome, occupational asthma, and others [2], [3]. Although existing journals in fields as diverse as paediatrics, internal medicine, allergy and pulmonology include articles on asthma, we believe that a journal entirely dedicated to asthma is both valuable and necessary. Moreover, we are committed to have a section devoted entirely to pediatric asthma, one of the most common chronic diseases of childhood in industrialized nations.

The title of this new journal include the word “practice” to emphasize our explicit intent to address practical aspects of asthma diagnosis and management, which are of greatest interest to the physicians and health care professionals caring for millions of children and adults with asthma worldwide. Thus, the Editors and the Editorial Board of ARP are committed to link mechanistic and practical knowledge of asthma in future years. We want to emphasize the strict cooperation between the Journal and Interasma [4]. This latter organization, founded in 1954 and currently chaired by Prof. G.W. Canonica, has the main missions of bridging the gaps between academy and clinical practice and of establishing an interdisciplinary forum on asthma worldwide. Notably, this mission is largely in agreement with that of ARP.

All manuscripts submitted to ARP will undergo a thorough peer-review process by physicians and scientists with relevant expertise. The Editorial Board [5] of ARP is committed to ensure a fair but reasonably expeditious peer-review process, followed by immediate online publication of accepted manuscripts as free articles, which will be accessible in PubMed. The Editors and the Editorial Board further commit and expect that ARP will rapidly get an Impact Factor that reflects the quality and value of this journal.

We would like to express our profound gratitude to our dear colleague and friend, Professor Carlos Baena-Cagnani. Carlos conceived and enthusiastically supported the preparation and launching of this journal, which is and will always be a tribute to his memory.

The first publications in ARP include two original research articles and a comprehensive review. The first article reports the findings of a Phase I clinical trial of vitamin D supplementation in patients with cystic fibrosis and allergic bronchopulmonary aspergillosis (ABPA), a condition that causes significant morbidity in patients with asthma [6]. Although preliminary by design, this Phase I trial demonstrates the efficacy of the tested dose of vitamin D (4,000 IU/day) in both achieving vitamin D sufficiency and reducing Th2 immune responses relevant to ABPA and other allergic conditions such as asthma. The second article reports the findings of an Italian questionnaire-based survey about respiratory allergy, as described by patients referred to pharmacists for their symptoms [7]. This aspect is of special interest, since pharmacists are usually the first-line referral. The Authors found that 11 % of patients who accessed pharmacies had only lower respiratory symptoms, but that a large fraction of the population had co-existing upper and lower respiratory symptoms. Notably, about 50 % of patients had not received a medical diagnosis, and thus self-management of repiratory symptoms was common. In spite of the limitations of the questionnaire-based design, those findings highlight the problems of under-diagnosis and under-treatment. The third article reviews current literature on the increasingly common “obese asthma” phenotype, including potential causes, modifiers and common co-morbidities; impact of overweight or obesity on asthma control; growing evidence of distinct endotypes of “obese asthma”; and treatment of patients with co-existing obesity and asthma[8].

We conclude by inviting all of our esteemed colleagues to submit their work to Asthma Research and Practice, while also welcoming their suggestions to improve the quality and reach of the journal.

Competing interests

The authors declare that they have no competing interests.


  1. Asthma Research and Practice. Accessed 29 May 2015.

  2. Asher MI, Stewart AW, Mallol J, Montefort S, Lai CK, Aït-Khaled N, Odhiambo J. Which population level environmental factors are associated with asthma, rhinoconjunctivitis and eczema? Review of the ecological analyses of ISAAC Phase OneRespir Res. 2010; 11:8. PubMed Abstract | BioMed Central Full Text OpenURL

  3. Papaiwannou A, Zarogoulidis P, Porpodis K, Spyratos D, Kioumis I, Pitsiou G, Pataka A, Tsakiridis K, Arikas S, Mpakas A, Tsiouda T, Katsikogiannis N, Kougioumtzi I, Machairiotis N, Siminelakis S, Kolettas A, Kessis G, Beleveslis T, Zarogoulidis K. Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): current literature reviewJ Thorac Dis. 2014; 6 Suppl 1:S146-51. PubMed Abstract | Publisher Full Text OpenURL

  4. Interasma. Accessed 29 May 2015.

  5. Asthma Research and Practice: Editorial Board. Accessed 29 May 2015.

  6. Nguyen N, Pilewski JM, Celdon JC, Mandalapu S, Blanchard ML, DeRicco A, et al. Vitamin D Supplementation Decreases Aspergillus fumigatus Specific Th2 Responses in CF Patients with Aspergillus sensitization: A Phase One Open-Label Study. Asthma Res Pract. doi:10.1186/s40733-015-0003-5.

  7. Lombardi CP. The patient with rhinitis in the pharmacy. A cross-sectional study in real life. Asthma Res Pract. doi:10.1186/s40733-015-0002-6.

  8. Baffi CW, Winnica DE, Holguin F. Asthma and Obesity: Mechanisms and Clinical Implications. Asthma Res Pract. doi:10.1186/s40733-015-0001-7.

    This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

    Sign up to receive new article alerts from Asthma Research and Practice   

The following new articles have just been published in Asthma Research and Practice

Juan Carlos Ivancevich Wednesday, 10 June 2015 15:12

The following new articles have just been published in Asthma Research and Practice

For articles using Author Version-first publication you will see a provisional PDF corresponding to the accepted manuscript. In these instances, the fully formatted Final Version PDF and full text (HTML) versions will follow in due course.


Asthma research and practice: a new journey begins

Celedon J, Passalacqua G, Canonica G

Asthma Research and Practice 2015, 1 :5 (4 June 2015)

Abstract | Full Text | PDF



The patient with rhinitis in the pharmacy. A cross-sectional study in real life

Lombardi C, Musicco E, Rastrelli F, Bettoncelli G, Passalacqua G, Canonica G

Asthma Research and Practice 2015, 1 :4 (4 June 2015)

Abstract | Full Text | PDF



Vitamin D supplementation decreases Aspergillus fumigatus specific Th2 responses in CF patients with aspergillus sensitization: a phase one open-label study

Nguyen N, Pilewski J, Celedón J, Mandalapu S, Blanchard M, DeRicco A, Hartigan E, Alcorn J, Kolls J

Asthma Research and Practice 2015, 1 :3 (4 June 2015)

Abstract | Full Text | PDF



Asthma and obesity: mechanisms and clinical implications

Baffi C, Winnica D, Holguin F

Asthma Research and Practice 2015, 1 :1 (4 June 2015)

Abstract | Full Text | PDF

Welcome to Fernando Holguin

Juan Carlos Ivancevich Tuesday, 02 June 2015 15:24

Welcome to Fernando Holguin, new AE for journal Research & Practice:

Asthma Research and Practice

Juan Carlos Ivancevich Thursday, 07 May 2015 13:21
Juan C. Celedón  University of Pittsburgh, United States - Giovanni Passalacqua  University of Genoa, Italy
Founding Editor 
Carlos E Baena-Cagnani Catholic University of Cordoba, Argentina
About Asthma Research and Practice This page includes information about the aims and scope of Asthma Research and Practice, editorial policies, open access and article-processing charges, the peer review process and other information. For details of how to prepare and submit a manuscript through the online submission system, please see the instructions for authors.
Accepting submissions

Interasma on Twitter

Interasma RT @worldallergy: WAO TV: Newer technologies to treat allergies and asthma - January 2019. Pinkus Goldberg, MD, Allergy Partners & Indiana…
Interasma RT @Aller_MD: Enterovirus as trigger of coeliac disease: Enterovirus in early childhood could be a trigger for later coeliac disease in chi…
Interasma RT @Aller_MD: Top story: Anaphylaxis Treatment: How to Avert This Severe Allergic Reaction | Everyday Health, see m…
Interasma RT @Aller_MD: “IMAGES IN CLINICAL MEDICINE: Sporotrichosis”
Interasma Interasma - Association of plasma soluble CD14 level with #asthma severity in adults: a case control study in China

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA